Biocon Limited, a global biopharmaceutical company, is focused on developing and supplying affordable medicines for
Biocon Limited has signed a licence agreement with Janssen Sciences Ireland for the commercialisation of
Biocon Limited (BSE: 532523, NSE: BIOCON) has received approval from the UK Medicines and Healthcare
Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited, has received a positive opinion from
Biocon Limited, a global biopharmaceutical company, has signed a partnership agreement with Bahiafarma and Bionovis
Biocon Limited has announced that its US subsidiary has received supplemental approval from the US
Biocon Limited, a global biopharmaceutical company, has announced the commercial launch of Yesafili™ (aflibercept-jbvf) in
Biocon Limited (BSE: 532523 | NSE: BIOCON), a global biopharmaceutical company, has announced the publication
Biocon Limited, a global biopharmaceutical company focused on affordable healthcare solutions, has reinforced its commitment
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from Health Canada for
